Using 3D bioprinting to revolutionize tissue testing VoxCell aims to provide a new platform for oncology drug screening. Their tissues are designed to mimic human-like cancer tissues that are used during… Read More
VANCOUVER, BC — Eyam Vaccines and Immunotherapeutics (Eyam), has announced a new licensing agreement for innovative vaccine technologies from the University of British Columbia (UBC), and The James Hutton Institute (JHI). The news comes with the recent development and advancements of new technologies for two novel vaccine vector platforms led by Professor Wilfred Jefferies of Michael Smith Laboratories in Vancouver, Canada, and Dr. Paolo Ribeca at JHI’s Biomathematics and Statistics Scotland in Edinburgh, Scotland.
VANCOUVER – University of British Columbia professor Sudip Shekhar is the first Canadian to receive the Schmidt Science Polymath award, which will grant his team roughly $3 million over a… Read More
Atlas’ stealth-stage company will leverage AbCellera’s technology to start and advance new drug programs with enhanced speed and capital efficiency VANCOUVER, BC & CAMBRIDGE, MASS.– AbCellera (Nasdaq: ABCL) and Atlas Venture announced a… Read More
IMscin001 study showed non-inferior levels of cancer immunotherapy Tecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung cancer Administered under the skin, the… Read More
